Who is sponsoring NCT03201094?

NCT03201094 is sponsored by University of Maryland, Baltimore.

What drugs are being tested in NCT03201094?

Interventions in NCT03201094: Neuromuscular Electrical Stimulation (NMES), High Protein Supplementation.

What condition does NCT03201094 study?

NCT03201094 studies Subarachnoid Hemorrhage, Muscle Atrophy, Inflammation, Nutritional and Metabolic Disease.

Is NCT03201094 still recruiting?

NCT03201094 is currently recruiting now. Last updated 15 October 2024.

Last reviewed 2024-10-15 · How we verify

NCT03201094

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Impact of NMES and HPRO on Recovery After SAH- Pilot Study

Recruiting now NA Last updated 15 October 2024

What this trial tests

NA trial testing Neuromuscular Electrical Stimulation (NMES) in Subarachnoid Hemorrhage in 30 participants. Currently enrolling.

Timeline

1 December 2017

Primary endpoint
31 May 2026

30 October 2026

Quick facts

Lead sponsor	University of Maryland, Baltimore
Phase	NA
Status	Recruiting now
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	single
Primary purpose	treatment
Enrollment	30
Start date	1 December 2017
Primary completion	31 May 2026
Estimated completion	30 October 2026
Sites	1 location across United States

Drugs / interventions tested

Neuromuscular Electrical Stimulation (NMES)
High Protein Supplementation

Conditions studied

Subarachnoid Hemorrhage — all drugs for Subarachnoid Hemorrhage →
Muscle Atrophy — all drugs for Muscle Atrophy →
Inflammation — all drugs for Inflammation →
Nutritional and Metabolic Disease — all drugs for Nutritional and Metabolic Disease →

Sponsor

University of Maryland, Baltimore

Who can join

18 and older, any sex, with Subarachnoid Hemorrhage or Muscle Atrophy. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The study purpose is to investigate the hypothesis that in adults with SAH, early neuromuscular electrical stimulation (NMES) and high protein supplementation (HPRO) will improve muscle mass, metabolic and inflammatory biomarker profiles, compared to SAH controls receiving standard of care interventions for nutrition and mobilization. The investigators will accomplish this by studying the effects of a high protein (HPRO) nutritional treatment as well as NMES intervention have upon muscle wasting and motor strength acutely after SAH. This will be addressed in a prospective trial of SAH patients receiving HRPO with NMES as compared to age and severity-matched SAH patients undergoing standard of care interventions for nutrition and mobilization. Additionally, the study will investigate the impact HPRO and NMES interventions have upon inflammatory cytokines and markers of energy balance. Results of this study will establish evidence for precision nutrition plus early exercise to mitigate the catabolic and inflammatory state produced by SAH to improve muscle, metabolic, and health recovery outcomes.

Publications & conference data

3 peer-reviewed publications reference this trial (live from Europe PMC):

Neuromuscular Electrical Stimulation and High-Protein Supplementation After Subarachnoid Hemorrhage: A Single-Center Phase 2 Randomized Clinical Trial.
Badjatia N, Sanchez S, Judd G, Hausladen R, et al · · 2021 · cited 24× · PMID 33150572 · DOI 10.1007/s12028-020-01138-4
Identification of metabolites associated with preserved muscle volume after aneurysmal subarachnoid hemorrhage due to high protein supplementation and neuromuscular electrical stimulation.
Gusdon AM, Savarraj JPJ, Feng D, Starkman A, et al · · 2024 · cited 5× · PMID 38956192 · DOI 10.1038/s41598-024-64666-5
17th Annual Meeting, Neurocritical Care Society, October 15-18, 2019, Vancouver, Canada.
· 2019 · cited 1× · PMID 31576484 · DOI 10.1007/s12028-019-00857-7

Verify or expand the search:

Other trials of Neuromuscular Electrical Stimulation (NMES)

Trials testing the same drug.

NCT07069257 — Effectiveness of Neuromuscular Electrical Stimulation Added to Oral Motor Therapy in Cerebral Palsy · NA · not yet recruiting
NCT07529210 — Effectiveness of Transcutaneous NMES as an Adjunct for Swallowing Disorders in Tracheotomized Patients · NA · not yet recruiting
NCT07380191 — EFFECT OF PLAZEPOD VERSUS ELECTRICAL STIMULATION ON RISK OF FALLING IN HEMODIALYSIS PATIENTS · NA · not yet recruiting
NCT07453485 — Immediate Effects of Neuromuscular Electrical Stimulation on Pain and Function in Achilles Tendon Disorders · NA · recruiting
NCT06692101 — Oral Care Strategies for Stroke Patients with Dysphagia · NA · completed

Other recruiting trials for Subarachnoid Hemorrhage

Currently open trials in the same condition.

NCT06797765 — Optical Coherence Tomography Angiography in Neurological Disease · recruiting
NCT06866210 — Risk Analysis of Intracranial Aneurysm Rupture Through Social Determinants of Health · active not recruiting
NCT06797752 — Effect of the Stellate Ganglion Block on the Retinal Microcirculation · recruiting
NCT06192342 — Ventilatory Parameters in Acute Neurological Injury · recruiting
NCT04459806 — Intracranial PrEssure Time dOse (ImPETO) · recruiting

Other University of Maryland, Baltimore trials

Trials by the same sponsor.

NCT07537413 — Ceftriaxone Dosage for Non-Critical Community-Acquired Pneumonia · Phase 4 · not yet recruiting
NCT07221799 — OER Glibenclamide for Neuropathic Pain in Multiple Sclerosis · Phase 1 · not yet recruiting
NCT07094672 — Development of an Opioid Withdrawal Clinical Outcome Assessment · not yet recruiting
NCT06583239 — Hub-Based Engagement Navigator Service to Reduce CSC Disengagement · NA · not yet recruiting
NCT07536412 — Decision Aid Efficacy in Low Risk Thyroid Cancer · NA · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03201094 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by University of Maryland, Baltimore
Last refreshed: 15 October 2024

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03201094.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing